GSK’s flop Potiga is picked up and headed for a quick makeover for pediatric epilepsy. Any bets on the prospective price?
GlaxoSmithKline took a considerable amount of heat last year when the pharma giant decided to yank a drug called Potiga, which had been approved as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
